Celldex Therapeutics, Inc. (CLDX)
| Market Cap | 1.36B |
| Revenue (ttm) | 4.14M |
| Net Income (ttm) | -77.02M |
| Shares Out | 46.75M |
| EPS (ttm) | -1.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 530,409 |
| Open | 29.16 |
| Previous Close | 28.92 |
| Day's Range | 27.56 - 30.66 |
| 52-Week Range | 26.26 - 57.20 |
| Beta | 2.70 |
| Analysts | Buy |
| Price Target | 66.13 (+126.8%) |
| Earnings Date | May 5, 2022 |
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response...
Financial Performance
In 2021, CLDX's revenue was $4.65 million, a decrease of -37.30% compared to the previous year's $7.42 million. Losses were -$70.51 million, 18.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for CLDX stock is "Buy." The 12-month stock price forecast is 66.13, which is an increase of 126.78% from the latest price.
News
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late...
HAMPTON, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with antih...
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update
HAMPTON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
HAMPTON, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporat...
Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call
HAMPTON, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to discu...
Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference
HAMPTON, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a virtual fireside chat at the 11th Annual SVB Leerin...
Is the Options Market Predicting a Spike in Celldex (CLDX) Stock?
Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis
HAMPTON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prurig...
Celldex to Participate in Upcoming Investor Conferences
HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferences...
Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -11.43% and -91.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update
HAMPTON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FMR LLC's Top 5 Buys in September
FMR LLC, the Boston-based asset management company commonly known as Fidelity, disclosed this month that its top-five trades during September included new buys in Toast Inc. ( TOST , Financial), Graphit...
Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clin...
- Rapid and sustained improvement in urticaria control after single dose of CDX-0159 - - Greatly improved patient quality of life and reduced disease impact - - Data further support 95% complete respons...
Celldex to Present at the 2021 Cantor Virtual Global Healthcare Conference
HAMPTON, N.J., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2021 Cantor Virtual Global He...
Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Acad...
HAMPTON, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements from the Phase 1b ...
Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study
Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.
Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study
HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CD...
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of 15.00% and 207.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Positive data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria presented at EAACI 2021 -
Will Celldex Therapeutics (CLDX) Report Negative Q2 Earnings? What You Should Know
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Good Were Celldex Therapeutics' Latest Clinical Results?
The short answer: They were impressive.
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option t...
HAMPTON, N.J., July 16, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offeri...
Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data
Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.